Liotta LA and Stetler-Stevenson WG, 1990, Metalloproteases and cancer invasion. Semin Cancer Biol, 99, 99–106.
Nakajima M, Welsch DR, Belloni PN and Nicolson GL, 1987, Degradation of basement membrane type IV collagen and lung subendothelial matrix by rat mammary adenocarcinoma cell clones of differing metastatic potentials. Cancer Res, 47, 4869–76.
Tryggvason K, Hoyhtya M and Salo T, 1987, Proteolytic degradation of extracellular matrix in tumor invasion. Biochem Biophys Acta, 907, 191–217.
Moll UM, Youngleib GL, Rosinski KB and Quigley JP, 1990, Tumor promoter stimulated Mr 92,000 gelatinase secreted by normal and malignant human cells: isolation and characterization of the enzyme from HT 1080 tumor cells. Cancer Res, 50, 6162–170.
Tryggvason K, Hoyhtya M and Pyke C, 1993, Type IV collagenases in invasive tumors. Breast Cancer Res Treat, 24, 209–18.
Nakajima M, Welsch DR, Wynn DM, Tsuruo T and Nicolson GL, 1993, Serum and plasma Mr 92,000 progelatinase levels correlate with spontaneous metastasis of rat 13762NF mammary adenocarcinoma. Cancer Res, 53, 5802–7.
Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM and Shafie S, 1980, Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature, 284, 67–8.
Angel P, Baumann I, Stein B, Delius H, Rahmsdorf HJ and Herrlich P, 1987, 12-O-Tetradecanoyl-phorbol-13-acetate induction of the human collagenase gene is mediated by an inducible enhancer element located in the 5′-flanking region. Mol Cell Biol, 7, 2256–66.
Webb P, Lopez GN, Uht RM and Kushner PJ, 1995, Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell specific estrogenlike effects of antiestrogens. Mol Endocr, 9, 443–56.
Jordan VC, 1986, Estrogen/Antiestrogen Action and Breast Cancer Therapy. University of Wisconsin Press.
Fornander T, Cedermark B, Mattsson A, et al.1989, Adjuvant tamoxifen in early breast cancer: occupance of new primary cancers. Lancet, 1, 117–19.
Boccardo F, Bruzzi P, Rubagotti A, Nicolo G and Rosso R, 1989, Estrogen like action of tamoxifen on vaginal epithelium in breast cancer patients. Oncology, 38, 281–5.
Fentimen IS and Powles TJ, 1987, Tamoxifen and benign breast problems. Lancet, 2, 1070–1.
Killackey MA, Hakes TB and Pierce VK, 1985, Endometrial adenocarcinoma in breast cancer patients receiving antiestrogen. Cancer tiTreat Rep, 69, 237–8.
Black LJ, Jones CD and Falcone JF, 1983, Antagonism of estrogen action with new benzothiophene-derived antiestrogen. Life Sci, 32, 1031–6.
Day BW, Magarian RA, Jain PT, Pento JT, Mousissian GK and Meyer K, 1991, Synthesis and biological evaluation of a series of 1,1,-dichloro-2,2,3-triaryl cyclopropanes as pure antiestrogens. J Med Chem, 34, 842–51.
Stobaugh JF, Magarian RA and Pento JT, 1982, Synthesis and biological evaluation of gem-dichlorocyclopropyl analogs of stilbene congeners as potential antiestrogens. J Pharm Sci, 71, 1126–9.
Jain PT, Pento JT, Magarian RA and Graves DC, 1991, Cytotoxicity of AnalogII in human breast cancer cells in culture. The Toxicologist, 11, 157.
Jain PT, Pento JT, Magarian RA and Graves DC, 1991, Antiproliferative activity of a series of novel cyclopropyl antiestrogens on MCF-7 human breast cancer cells in culture. Anti Cancer Drugs, 2, 487–93.
DeFriend DJ, Anderson E, Bell J, et al.1994, Effect of 4-hydroxytamoxifen and a novel pure antiestrogen (ICI-182,780) on the clonogenic growth of human breast cancer cells in vitro. Br J Cancer, 70, 204–11.
Hu FX, Veroni M, De Luise M, et al.1993, Circumvention of tamoxifen resistance by the pure antiestrogen ICI-182,780. Int J Cancer, 55, 873–6.
Jain PT and Pento JT, 1991, A vehicle for the evaluation of hydrophobic compounds in cell culture. Res Comm Chem Path Pharm, 74, 105–16.
Howard EW, Bullen EC and Banda MJ, 1991, Regulation of the autoactivation of human 72 kDa progelatinase by tissue inhibitor of metalloproteinase-2. J Biol Chem, 226, 13064–9.
Thompson EW, Reich R, Shima TB, et al.1988, Differential regulation of growth and invasiveness of MCF-7 breast cancer cells by antiestrogens. Cancer Res, 48, 6764–8.
Heussen C and Dowdle EB, 1980, Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Analyt Biochem, 102, 196–202.
Kao RT and Stern R, 1986, Collagenases in human breast carcinoma cell lines. Cancer Res, 46, 1349–54.
Brown PD, Levy AT, Margulies IMK, Liotta LA and Stetler-Stevenson WG, 1990, Independent expression and cellular processing of Mr 72 kDa type IV collagenase and interstitial collagenase in human tumorigenic cell lines. Cancer Res, 50, 6184–91.
Overall CM, Wrana JL and Sodek J, 1989, Independent regulation of collagenase, 72 kDa progelatinase and metalloendoproteinase inhibitor expression in human fibroblasts by transforming growth factor-β. J Biol Chem, 264, 1860–9.
Duffy MJ, 1992, The role of proteolytic enzymes in cancer invasion and metastasis. Clin Exp Metastasis, 10, 145–55.
Mueller SC, Yeh Y and Chen WT, 1992, Tyrosine phosphate regulation of membrane proteins mediates cellular invasion by transformed cells. J Cell Biol, 119, 1319–25.
Monsky WL, Kelly T, Lin CY, et al.1993, Binding and localization of Mr 72,000 matrix metalloproteinase at cell surface invadopodia. Cancer Res, 53, 3159–64.
Emonard HP, Remacle AG, Noel AC, Grimand JA, Stetler-Stevenson WG and Foidart JM, 1992, Tumor cell surface associated receptor for the Mr 72,000 type IV collagenase. Cancer Res, 52, 5845–8.
Abidi SMA, Howard EW and Pento JT, 1996, Influence of antiestrogens on the release of plasminogen activator by human breast cancer cells. AACR Special Conference: Proteases and Protease Inhibitors, A–45.
Paranjpe M, Engel L, Young N and Liotta LA, 1980, Activation of human breast carcinoma collagenase through plasminogen activator. Life Sci, 26, 1223–31.
Katzenellenbogen BS, Norman JM, Eckert RL, Peltz SW and Mangel WF, 1984, Bioactivities, estrogen receptor interaction and plaminogen activatorinducing activities of tamoxifen and hydroxytamoxifen isomers in MCF-7 human breast cancer cells. Cancer Res, 44, 112–19.
Black LJ and Goode RL, 1981, Evidence for biological action of the antiestrogens LY117018 and tamoxifen by different mechanisms. Endocrinology, 109, 987–9.
Turner R and Tjian R, 1989, Leucine repeats and an adjacent DNA binding domain mediate the formation of functional cfos-cjun heterodimers. Science, 243, 1689–94.
Sassone-Corsi P, Lamph WW, Kamps M and Verma IM, 1988, Fos-associated cellular p35 is related to nuclear transcription factor AP-1. Cell, 54, 553–60.
Huhtala P, Chow LT and Tryggvason K, 1990, Structure of the human type IV collagenase gene. J Biol Chem, 265, 11077–82.
Huhtala P, Tuuttila A, Chow LT, Lohi J, Keski-Oja J and Tryggvason K, 1991, Complete structure of the human gene for 92kDa type IV collagenase. Divergent regulation of expression for the 92-and 72-kilodalton enzyme genes in HT-1080 cells. J Biol Chem, 266, 16485–90. 1 1 1 1